Articles tagged "Immunosuppression"

2022 American Transplant Congress
Pegloticase Use in Renal Transplant Recipients with Gout: Findings from an Insurance Claims Database Study
C. A. Shadur¹, B. Marder², C. Vesel², B. LaMoreaux²
¹Iowa Kidney Physicians, Des Moines, IA, ²Horizon Therapeutics plc, Deerfield, IL
*Purpose: Kidney transplant (KT) recipients have high gout incidence due to reduced eGFR and medication use associated with hyperuricemia.1 Oral urate-lowering therapies in KT patients…
2022 American Transplant Congress
Comparing The Immunologic Responses Between Kidney Transplant Recipients Receiving Standard Immunosuppression And CNI Reduction After Two Doses Of ChAdOx-1 And A Booster Dose BNT162b2
S. Phirom¹, T. Kitrungphaiboon², W. Jantarabenjakul², Y. Avihingsanon², W. Prasithsirikul³, J. Vanichanan⁴, P. Hansasuta⁵, N. Townamchai⁶
¹Nephrology division, Department of medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ²King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ³Bamrasnaradura infectious disease institute, Bangkok, Thailand, ⁴Infectious diseases, Department of medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ⁵Department of Microbiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, ⁶Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
*Purpose: Immunosuppression can impair immunological responses after vaccination in kidney transplant recipients (KTR). However, little is known about the effect of the booster dose of…
2022 American Transplant Congress
Recipient and Center Factors Associated with Immunosuppression Practice Beyond the First Year After Liver Transplantation
T. Bittermann¹, D. Goldberg²
¹University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL
*Purpose: To investigate patient and center factors associated with differences in immunosuppression management in the first 5 years after LT.*Methods: A retrospective cohort of 11,326…
2022 American Transplant Congress
Association Between Time in Therapeutic Range for Warfarin and Time in Therapeutic Range for Calcineurin Inhibitors in Patients That Received Left Ventricular Assist Devices as Bridge to Transplant
G. Flajc¹, X. Huang², C. Minard², M. Manson¹, Z. Truman¹
¹Baylor St. Luke's Medical Center, Houston, TX, ²Baylor College of Medicine, Houston, TX
*Purpose: Medication nonadherence is a leading cause of avoidable graft failure post-transplant. The relationship between medication adherence in patients with left ventricular assist devices (LVADs)…
2022 American Transplant Congress
Donor-Specific T Cell Senescence In Operationally Tolerant Liver Transplant Recipients
K. Deng¹, N. Tanimine², C. Breeden³, B. Burrell³, G. Gaile³, K. Lee¹, R. Matheson¹, F. Qiang¹, C. Rickert¹, C. LeGuern¹, J. Markmann¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Department of Gastroenterological and Transplantation Surgery, Hiroshima University, Hiroshima, Japan, ³Immune Tolerance Network, Bethesda, MD
*Purpose: Recent evidence indicates a correlation in liver transplant recipients between successful operational tolerance (OT) post immunosuppression withdrawal (ISW) with both recipient age and time…
2022 American Transplant Congress
Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial
A. Ajlan¹, H. Aleid¹, T. Ali¹, H. Joharji¹, Z. Alabdulkarim¹, T. Aburiash¹, K. Almeshari¹, A. Nazmi¹, Y. Shah¹, E. Devol¹, D. Alkortas¹, D. Broering¹, I. Alahmadi¹, A. Ullah¹, A. Alotaibi¹, A. Aljedai²
¹KFSHRC, RIYADH, Saudi Arabia, ²MOH, RIYADH, Saudi Arabia
*Purpose: To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC…
2022 American Transplant Congress
Impact of Belatacept on Clinical Outcomes in Lung Transplant Patients with Antibody-Mediated Rejection
L. Zaffiri, R. Hallak, S. Leonard, M. Neely, A. Hulber, H. Berry, K. A. Young, J. M. Reynolds
Duke University, Durham, NC
*Purpose: Antibody-mediated rejection (AMR) is cause of significant morbidity and mortality in lung transplant recipients (LTRs). An optimal therapeutic regimen is still lacking. Recent evidence…
2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
P. A. Jacobson¹, A. Saqr¹, M. Al-Kofahi¹, D. P. Schladt², W. Guan³, W. S. Oetting¹, R. Mannon⁴, C. R. Dorr⁵, R. P. Remmel¹, G. C. Onyeaghala⁶, B. Wu³, A. K. Israni⁷, A. Matas⁸
¹Univ of MN, College of Pharmacy, Minneapolis, MN, ²Hennepin Health Research Institute, Minneapolis, MN, ³Univ of MN, Biostatistics, Minneapolis, MN, ⁴Univ of Nebraska, Dept of Medicine, Omaha, NE, ⁵Hennepin Health Research Institute and Dept of Medicine, Minneapolis, MN, ⁶Hennepin Healthcare Research Institute, Minneapolis, MN, ⁷Hennepin Health Dept of Medicine and Univ of MN, Minneapolis, MN, ⁸University of MN, Dept of Surgery, Minneapolis, MN
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…
2022 American Transplant Congress
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus
R. Zhang¹, S. Ge¹, M. Chu¹, J. Kahwaji², A. Karasyov¹, D. Lovato¹, A. Vo², J. Choi², M. Toyoda¹, S. Jordan²
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Post-transplant immunosuppression with “everolimus + reduced dose tacrolimus” (Ev + Taclow) is reported to reduce the risk of viral infections compared to standard doses…
2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
E. Siskind¹, J. Splinter¹, C. Taing¹, A. Adekile², S. Njim¹, S. Shah¹, R. Plews³, D. Conti⁴, S. Patel²
¹Center for Transplantation, University Medical Center of Southern Nevada, Las Vegas, NV, ²University Medical Center of Southern Nevada, Las Vegas, NV, ³Center for Transplantation, Albany Medical Center, Albany, NY, ⁴Albany Medical Center, Albany, NY
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…

1
2
3
…
138
Next Page »